New oral anticoagulants for atrial fibrillation

Circulation

Volumn 126, Issue 1, 2012, Pages 133-137

  Spinler, Sarah A ^a   Shafir, Valerie ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AMPRENAVIR; APREPITANT; ATAZANAVIR; BOSENTAN; CARBAMAZEPINE; CIPROFLOXACIN; CLARITHROMYCIN; CONIVAPTAN; CYCLOSPORIN; DABIGATRAN ETEXILATE; DARUNAVIR; EFAVIRENZ; ETRAVIRINE; HYPERICUM PERFORATUM EXTRACT; INDINAVIR; ITRACONAZOLE; NAFCILLIN; NEFAZODONE; NELFINAVIR; PHENYTOIN; RIFAMPICIN; RITONAVIR; RIVAROXABAN; SAQUINAVIR; TELAPREVIR; TELITHROMYCIN; VORICONAZOLE; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CASE REPORT; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG CONTRAINDICATION; DYSPEPSIA; FEMALE; GRAPEFRUIT JUICE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERICUM PERFORATUM; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; DRUG SUBSTITUTION; FEMALE; HUMANS; MALE; MORPHOLINES; PRACTICE GUIDELINES AS TOPIC; PYRIDINES; THIOPHENES;

EID: 84863608998     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.099283     Document Type: Article

References (16)

1. Pradaxa (dabigatran etexilate capsules) prescribing information. Boehringer Ingelheim Pharmaceuticals Inc; Ridgefield, CT: January 2012.
2. Connolly SJ, Ezekowitz MD, Yusef S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lews BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
3. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363:1875-1876.
4. U.S. Food and Drug Administration. Drug development and drug interactions: table of substrates, inhibitors and inducers. http://www. fda.gov/drugs/developmentapprovalprocess/developmentresources/ druginteractionslabeling/ucm093664.htm#inhibitors. Accessed March 29, 2012.
5. Rivaroxaban (Xarelto rivaroxaban tablets) prescribing information. Janssen Pharmaceuticals Inc; Titusville, NJ: December 2011.
6. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365:883-891.
7. Wann LS, Curtis AB, Ellenbogen KA, Estes NAM, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracey CM, Jacobs AK. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011; 123:1144-1150.
8. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughs M, Spencer FA, Manning WJ, Halperin JL, Lip GYH. Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(SUPPL.): e531S-e575S.
9. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines Chest. 2012;141;e44S-e88S.
10. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, Albers GW. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control. Arch Intern Med. 2007;167:239-245.
11. Rosendaal FR, Cannegieter SC, van der Meer FJM, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236-239. (Pubitemid 23069000)
12. Wallentin L, Yusef S, Ezekowitz, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376:975-983.
13. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011;123:2562-2570.
14. Xarelto FDA Draft Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC). Available from: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeeting Materials/Drugs/CardiovascularandRenal DrugsAdvisoryCommittee/UCM270796. pdf. Accessed February 9, 2012.
15. Lane DA, Lip GY. Quality of anticoagulation control in atrial fibrillation. Lancet. 2010;376:935-937.
16. Spinler SA, Willey VJ. A patient's guide to taking dabigatran etexilate. Circulation. 2011;124:e209-e211.